The message comes after remdesivir has undergone a study in the US of over 1000 severely ill patients, TV4 News reports.

- We have received results from clinical studies that we are currently looking at in a common EU system, so it will be a joint decision, says Charlotta Bergquist, group manager for the infection group at the Swedish Medicines Agency

Several studies

What you do now, according to Charlotta Bergquist, is to look at the balance between the benefits and the risks of the drug. She has difficulty answering exactly when a message may come.

- I can only say that we work as fast as we can.

Earlier this week, the US Health Authority released preliminary results from the study showing that patients treated with remdesivir recovered more quickly from the disease compared to a control group that did not receive the medication.

But the effect of the drug has nevertheless been questioned, among other things, since a Chinese study of 200 people on the contrary found no evidence that remdesivir accelerated recovery or reduced mortality.

"No common approval"

US Food and Drug Administration On Friday, the FDA issued a warning sign for emergency treatment of covid-19 patients with remedies.

"It is not an ordinary approval, but it is some kind of emergency measure that they have done," says Charlotta Bergquist.

Remdesivir was developed to be used against Ebola but did not prove effective enough. The medicine stops the RNA virus from multiplying - and is rather a brake medicine than a cure.